市場調査レポート
商品コード
1108385

遺伝子治療の世界市場:ベクター別 (非ウイルス性 (オリゴヌクレオチド)、ウイルス性 (レトロウイルス、アデノ随伴))・適応症別 (がん、神経疾患、肝疾患、デュシェンヌ型筋ジストロフィー)・送達方法別 (体内、体外)・地域別の将来予測 (2027年)

Gene Therapy Market by Vectors (Non-viral(Oligonucleotides), Viral(Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method(In Vivo, Ex Vivo), Region -Global Forecast -2027

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 154 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
遺伝子治療の世界市場:ベクター別 (非ウイルス性 (オリゴヌクレオチド)、ウイルス性 (レトロウイルス、アデノ随伴))・適応症別 (がん、神経疾患、肝疾患、デュシェンヌ型筋ジストロフィー)・送達方法別 (体内、体外)・地域別の将来予測 (2027年)
出版日: 2022年07月27日
発行: MarketsandMarkets
ページ情報: 英文 154 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の遺伝子治療市場は、2022年に73億米ドルと推定され、2027年には172億米ドルに達すると予測され、予測期間中のCAGRは18.6%と予測されています。

神経疾患やがんの症例増加、遺伝子治療製品の認可件数の増加、遺伝子治療関連の研究開発への投資の増加といった要因が、市場の成長を促進しています。しかし、遺伝子治療にかかる費用が高いことなどが、この市場の成長を抑制しています。

"遺伝子治療市場の適応症別では、予測期間中、がん分野が最も高い成長率を占める"

2021年、がんセグメントが最も高い成長率を占めました。世界中でがんの疾病負担が増加していることと、がんを治療するための遺伝子治療に対する需要が高まっていることが、予測期間においてがんのセグメント成長を増大させるでしょう。

"アジア太平洋:遺伝子治療市場で最も急速に成長している地域"

アジア太平洋は、予測期間中に最も高いCAGRを記録すると予測されています。この市場の高い成長率は、新興国での医療費の改善や、製品上市の増加、がん・神経疾患の発生率の増加などに起因しています。

目次

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概略

  • イントロダクション
  • 市場力学
  • 価格分析
  • 技術分析
  • サプライチェーン分析
    • 大手企業
    • 中小企業 (SME)
    • エンドユーザー
  • エコシステム分析
  • 主な会議とイベント (2022年~2023年)
  • 規制分析
  • ポーターのファイブフォース分析
  • 主な利害関係者と購入基準

第6章 遺伝子治療市場:ベクター別

  • イントロダクション
  • 非ウイルス性ベクター
    • オリゴヌクレオチド
    • その他の非ウイルスベクター
  • ウイルス性ベクター
    • レトロウイルスベクター
    • アデノ随伴ウイルスベクター
    • その他のウイルスベクター

第7章 遺伝子治療市場:適応症別

  • イントロダクション
  • 神経疾患
  • がん
  • DMD (デュシェンヌ型筋ジストロフィー)
  • 肝疾患
  • その他の適応症

第8章 遺伝子治療市場:送達方法別

  • イントロダクション
  • 体内 (In Vivo) 遺伝子治療
  • 体外 (In Vitro) 遺伝子治療

第9章 遺伝子治療市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • 他の欧州諸国
  • アジア太平洋
    • 日本
    • 中国
    • 他のアジア太平洋諸国
  • その他の地域

第10章 競合情勢

  • 概要
  • 市場シェア分析 (2021年)
  • 主要企業の収益シェア分析
  • 企業評価クアドラント
  • 企業フットプリント分析
    • 企業の製品フットプリント
  • 競合シナリオ

第11章 企業プロファイル

  • BIOGEN
  • SAREPTA THERAPEUTICS
  • GILEAD SCIENCES, INC.
  • AMGEN, INC.
  • NOVARTIS AG
  • ORCHARD THERAPEUTICS PLC
  • SPARK THERAPEUTICS, INC. (F. HOFFMANN-LA ROCHEの子会社)
  • AGC BIOLOGICS
  • ANGES, INC.
  • BLUEBIRD BIO, INC.
  • JAZZ PHARMACEUTICALS PLC
  • DYNAVAX TECHNOLOGIES
  • HUMAN STEM CELLS INSTITUTE
  • SIBIONO GENETECH CO., LTD.
  • SHANGHAI SUNWAY BIOTECH CO., LTD.
  • UNIQURE N.V.
  • GENSIGHT BIOLOGICS S.A.
  • CELGENE CORPORATION (BRISTOL-MYERS SQUIBBの子会社)
  • CELLECTIS
  • SANGAMO THERAPEUTICS
  • MUSTANG BIO
  • AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
  • POSEIDA THERAPEUTICS, INC.

第12章 付録

目次
Product Code: BT 7506

The global gene therapy market is valued at an estimated USD 7.3 billion in 2022 and is projected to reach USD 17.2 billion by 2027, at a CAGR of 18.6% during the forecast period. Factors such asrising cases of neurological diseases and cancer, growing gene therapy product approvals, and increasing investment in gene therapy related research and development drive the market growth. However,factors like high cost of gene therapy is restraining the growth of this market.

"The cancer segment accounted for the highest growth ratein the gene therapy market, by indication, during the forecast period"

In 2021, cancer segment accounted for the highest growth rate. Growing disease burden of cancer across the globe coupled with rising demand for gene therapies to treat cancer will augment the segmental growth of cancer over the forecast period.

"Asia Pacific: The fastest-growing region in the gene therapy market"

The Asia Pacific market is estimated to record the highest CAGR during the forecast period. The high growth rate of this market can be attributed to the improving healthcare expenditure in emerging economies, increasing product launches, and increasing incidence of cancer and neurological diseases.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1- 32%, Tier 2- 44%, and Tier 3-24%
  • By Designation: C-level (Managers) - 30%, D-level(CXOs, Directors)- 34%, and Others (Executives) - 36%
  • By Region: North America -50%, Europe -32%, Asia-Pacific -10%, Rest of the World -8%

List of Companies Profiled in the Report:

  • Biogen (US)
  • Sarepta Therapeutics (US)
  • Gilead Sciences, Inc. (US)
  • Amgen, Inc. (US)
  • Novartis AG (Switzerland)
  • Orchard Therapeutics Plc (UK)
  • Spark Therapeutics, Inc. (A Part Of ‎F. Hoffmann-La Roche) (US)
  • AGC Biologics (US)
  • Anges, Inc. (Japan)
  • Bluebird Bio, Inc. (US)
  • Jazz Pharmaceuticals Plc (Ireland)
  • Dynavax Technologies (US)
  • Human Stem Cells Institute (Russia)
  • SibionoGenetech Co., Ltd. (China)
  • Shanghai Sunway Biotech Co., Ltd. (China)
  • Uniqure N.V. (Netherland)
  • Gensight Biologics S.A. (France)
  • Celgene Corporation (A Bristol-Myers Squibb Company) (US)
  • Cellectis (France)
  • Sangamo Therapeutics (US)
  • Mustang Bio (US)
  • AGTC (Applied Genetic Technologies Corporation) (US)
  • Poseida Therapeutics, Inc. (US)

Research Coverage:

This report provides a detailed picture of the global gene therapy market. It aims at estimating the size and future growth potential of the market across different segments such as vectors, indication, delivery method, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, challenges,trends,and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • FIGURE 2 KEY DATA FROM SECONDARY SOURCES
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.2 COMPANY REVENUE ANALYSIS
    • FIGURE 4 COMPANY REVENUE ANALYSIS
    • 2.2.3 GROWTH FORECAST
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 5 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

    • FIGURE 6 GENE THERAPY MARKET, BY VECTOR, 2022 VS. 2027 (USD MILLION)
    • FIGURE 7 GENE THERAPY MARKET, BY DELIVERY METHOD, 2022 VS. 2027 (USD MILLION)
    • FIGURE 8 GENE THERAPY MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 GENE THERAPY MARKET: REGIONAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 GENE THERAPY MARKET OVERVIEW
    • FIGURE 10 HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2021)
    • FIGURE 11 NON-VIRAL VECTORS DOMINATE NORTH AMERICAN GENE THERAPY MARKET
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET
    • FIGURE 12 APAC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 13 GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 High incidence of cancer and other target diseases
    • TABLE 1 NUMBER OF NEW CANCER CASES, 2020 VS. 2025
      • 5.2.1.2 Product approvals
    • TABLE 2 PRODUCT APPROVALS, 2015-2021
      • 5.2.1.3 Funding for gene therapy research
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Strong product pipeline
    • TABLE 3 GENE THERAPY MARKET: INDICATIVE LIST OF PIPELINE DRUGS
    • 5.2.3 CHALLENGES
      • 5.2.3.1 High treatment costs
    • TABLE 4 PRICE OF GENE THERAPY PRODUCTS, 2021
  • 5.3 PRICING ANALYSIS
  • 5.4 TECHNOLOGY ANALYSIS
    • FIGURE 14 KEY STEPS IN GENE THERAPY
  • 5.5 SUPPLY CHAIN ANALYSIS
    • 5.5.1 PROMINENT COMPANIES
    • 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES (SMES)
    • 5.5.3 END USERS
    • FIGURE 15 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS OF GENE THERAPY MARKET
    • TABLE 5 STAKEHOLDERS IN THE GENE THERAPY ECOSYSTEM AND THEIR ROLES
  • 5.7 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 6 GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.8 REGULATORY ANALYSIS
    • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 11 GENE THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF SUPPLIERS
    • 5.9.4 BARGAINING POWER OF BUYERS
    • 5.9.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
  • 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 16 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GENE THERAPY PRODUCTS
    • 5.10.2 BUYING CRITERIA FOR GENE THERAPY PRODUCTS
    • FIGURE 17 KEY BUYING CRITERIA FOR END USERS

6 GENE THERAPY MARKET, BY VECTOR

  • 6.1 INTRODUCTION
    • TABLE 12 GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
  • 6.2 NON-VIRAL VECTORS
    • TABLE 13 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 14 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • 6.2.1 OLIGONUCLEOTIDES
      • 6.2.1.1 Oligonucleotides account for the largest share of the non-viral vectors market
    • TABLE 15 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • 6.2.2 OTHER NON-VIRAL VECTORS
    • TABLE 16 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 VIRAL VECTORS
    • TABLE 17 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 18 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • 6.3.1 RETROVIRAL VECTORS
    • TABLE 19 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 20 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
      • 6.3.1.1 Gamma-retroviral vectors
        • 6.3.1.1.1 Availability of wide range of gamma-retroviral vectors supports market growth
    • TABLE 21 GENE THERAPY MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)
      • 6.3.1.2 Lentiviral vectors
        • 6.3.1.2.1 North America to dominate lentiviral vectors market
    • TABLE 22 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.2 ADENO-ASSOCIATED VIRUS VECTORS
      • 6.3.2.1 Potential applications in in vivo applications to drive interest in AAV vectors
    • TABLE 23 GENE THERAPY MARKET FOR AAV VECTORS, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.3 OTHER VIRAL VECTORS
    • TABLE 24 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)

7 GENE THERAPY MARKET, BY INDICATION

  • 7.1 INTRODUCTION
    • TABLE 25 GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
  • 7.2 NEUROLOGICAL DISEASES
    • 7.2.1 NEUROLOGICAL DISEASES TO FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET
    • TABLE 26 GENE THERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 CANCER
    • 7.3.1 GROWING DEMAND FOR CANCER THERAPIES TO DRIVE MARKET GROWTH
    • TABLE 27 NUMBER OF NEW CANCER CASES, BY TYPE, 2020-2040
    • TABLE 28 GENE THERAPY MARKET FOR CANCER, BY REGION, 2020-2027 (USD MILLION)
  • 7.4 DUCHENNE MUSCULAR DYSTROPHY
    • 7.4.1 RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH
    • TABLE 29 GENE THERAPY MARKET FOR DMD, BY REGION, 2020-2027 (USD MILLION)
  • 7.5 HEPATOLOGICAL DISEASES
    • 7.5.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS TO SUPPORT MARKET GROWTH
    • TABLE 30 GENE THERAPY MARKET FOR HEPATOLOGICAL DISEASES, BY REGION, 2020-2027 (USD MILLION)
  • 7.6 OTHER INDICATIONS
    • TABLE 31 GENE THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2020-2027 (USD MILLION)

8 GENE THERAPY MARKET, BY DELIVERY METHOD

  • 8.1 INTRODUCTION
    • TABLE 32 GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
  • 8.2 IN VIVO GENE THERAPY
    • 8.2.1 IN VIVO GENE THERAPY TO DOMINATE MARKET
    • TABLE 33 IN VIVO GENE THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.3 EX VIVO GENE THERAPY
    • 8.3.1 EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGH GROWTH
    • TABLE 34 EX VIVO GENE THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION)

9 GENE THERAPY MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 35 GENE THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 18 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
    • TABLE 36 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 38 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 41 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 42 NORTH AMERICA: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 US dominates the global gene therapy market
    • TABLE 43 LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES
    • TABLE 44 US FDA GENE THERAPY PRODUCT APPROVALS
    • TABLE 45 US: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 46 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 47 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 48 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 49 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 50 US: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Growing burden of cancer supports market growth in Canada
    • TABLE 51 CANADA: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 52 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 53 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 56 CANADA: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 57 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 58 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 59 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 60 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 63 EUROPE: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany dominates European gene therapy market
    • TABLE 64 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 65 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 66 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 67 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 69 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 70 GERMANY: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.3.2 FRANCE
      • 9.3.2.1 Increasing cancer incidence to support market growth
    • TABLE 71 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 72 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 73 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 74 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 75 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 77 FRANCE: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.3.3 UK
      • 9.3.3.1 Rising incidence of melanoma to support market growth in UK
    • TABLE 78 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 79 UK: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 80 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 81 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 82 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 83 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 84 UK: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 High incidence of targeted diseases and increasing healthcare spending to drive Italian market growth
    • TABLE 85 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 86 ITALY: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 87 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 88 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 89 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 90 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 91 ITALY: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Rising cancer incidence and increasing healthcare expenditure to support market growth in Spain
    • TABLE 92 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 93 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 94 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 95 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 96 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 98 SPAIN: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 99 ROE: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 100 ROE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 101 ROE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 102 ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 103 ROE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 104 ROE: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 19 ASIA PACIFIC: GENE THERAPY MARKET SNAPSHOT
    • TABLE 105 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 107 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 108 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 109 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.4.1 JAPAN
      • 9.4.1.1 Japan dominates the APAC gene therapy market
    • TABLE 112 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 113 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 114 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 115 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 116 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 117 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 118 JAPAN: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.4.2 CHINA
      • 9.4.2.1 Rising prevalence of cancer and established base for gene therapy to support market growth in China
    • TABLE 119 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 120 CHINA: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 121 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 122 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 123 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 124 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 125 CHINA: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    • 9.4.3 REST OF ASIA PACIFIC
    • TABLE 126 ROAPAC: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 127 ROAPAC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 128 ROAPAC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 129 ROAPAC: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 130 ROAPAC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 131 ROAPAC: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)
  • 9.5 REST OF THE WORLD
    • TABLE 132 ROW: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)
    • TABLE 133 ROW: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 134 ROW: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION)
    • TABLE 135 ROW: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 136 ROW: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 137 ROW: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
    • FIGURE 20 KEY DEVELOPMENTS IN THE GENE THERAPY MARKET
  • 10.2 MARKET SHARE ANALYSIS, 2021
    • FIGURE 21 GENE THERAPY MARKET SHARE ANALYSIS, 2021
    • TABLE 138 GENE THERAPY MARKET: DEGREE OF COMPETITION
  • 10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 22 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN GENE THERAPY, 2019-2021
  • 10.4 COMPANY EVALUATION QUADRANT
    • 10.4.1 STARS
    • 10.4.2 EMERGING LEADERS
    • 10.4.3 PERVASIVE PLAYERS
    • 10.4.4 PARTICIPANTS
    • FIGURE 23 GENE THERAPY MARKET: COMPANY EVALUATION QUADRANT, 2021
  • 10.5 COMPANY FOOTPRINT ANALYSIS
    • 10.5.1 PRODUCT FOOTPRINT OF COMPANIES
    • TABLE 139 GENE THERAPY MARKET: COMPANY PRODUCT FOOTPRINT (2021) ACROSS INDICATIONS
  • 10.6 COMPETITIVE SCENARIO
    • TABLE 140 PRODUCT APPROVALS, 2018-2022
    • TABLE 141 DEALS, 2018-2022
    • TABLE 142 OTHER DEVELOPMENTS, 2018-2022

11 COMPANY PROFILES

  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
  • 11.1 BIOGEN
    • TABLE 143 BIOGEN: BUSINESS OVERVIEW
    • FIGURE 24 BIOGEN: COMPANY SNAPSHOT
  • 11.2 SAREPTA THERAPEUTICS
    • TABLE 144 SAREPTA THERAPEUTICS: BUSINESS OVERVIEW
    • FIGURE 25 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
  • 11.3 GILEAD SCIENCES, INC.
    • TABLE 145 GILEAD SCIENCES INC: BUSINESS OVERVIEW
    • FIGURE 26 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • 11.4 AMGEN, INC.
    • TABLE 146 AMGEN INC: BUSINESS OVERVIEW
    • FIGURE 27 AMGEN, INC.: COMPANY SNAPSHOT
  • 11.5 NOVARTIS AG
    • TABLE 147 NOVARTIS AG: BUSINESS OVERVIEW
    • FIGURE 28 NOVARTIS AG: COMPANY SNAPSHOT
  • 11.6 ORCHARD THERAPEUTICS PLC
    • TABLE 148 ORCHARD THERAPEUTICS PLC: BUSINESS OVERVIEW
    • FIGURE 29 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT
  • 11.7 SPARK THERAPEUTICS, INC. (AN F. HOFFMANN-LA ROCHE COMPANY)
    • TABLE 149 SPARK THERAPEUTICS INC: BUSINESS OVERVIEW
  • 11.8 AGC BIOLOGICS
    • TABLE 150 AGC BIOLOGICS: BUSINESS OVERVIEW
  • 11.9 ANGES, INC.
    • TABLE 151 ANGES INC: BUSINESS OVERVIEW
    • FIGURE 30 ANGES, INC.: COMPANY SNAPSHOT
  • 11.10 BLUEBIRD BIO, INC.
    • TABLE 152 BLUEBIRD BIO: BUSINESS OVERVIEW
    • FIGURE 31 BLUEBIRD BIO: COMPANY SNAPSHOT
  • 11.11 JAZZ PHARMACEUTICALS PLC
    • TABLE 153 JAZZ PHARMACEUTICALS: BUSINESS OVERVIEW
    • FIGURE 32 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT
  • 11.12 DYNAVAX TECHNOLOGIES
    • TABLE 154 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW
    • FIGURE 33 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
  • 11.13 HUMAN STEM CELLS INSTITUTE
    • TABLE 155 HUMAN STEM CELLS INSTITUTE: BUSINESS OVERVIEW
  • 11.14 SIBIONO GENETECH CO., LTD.
    • TABLE 156 SIBIONO GENETECH CO LTD: BUSINESS OVERVIEW
  • 11.15 SHANGHAI SUNWAY BIOTECH CO., LTD.
    • TABLE 157 SHANGHAI SUNWAY BIOTECH CO LTD: BUSINESS OVERVIEW
  • 11.16 UNIQURE N.V.
    • TABLE 158 UNIQURE NV: BUSINESS OVERVIEW
  • 11.17 GENSIGHT BIOLOGICS S.A.
    • TABLE 159 GENSIGHT BIOLOGICS SA: BUSINESS OVERVIEW
  • 11.18 CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
    • TABLE 160 CELGENE CORPORATION: BUSINESS OVERVIEW
  • 11.19 CELLECTIS
    • TABLE 161 CELLECTIS: BUSINESS OVERVIEW
  • 11.20 SANGAMO THERAPEUTICS
    • TABLE 162 SANGAMO THERAPEUTICS: BUSINESS OVERVIEW
  • 11.21 MUSTANG BIO
    • TABLE 163 MUSTANG BIO: BUSINESS OVERVIEW
  • 11.22 AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
    • TABLE 164 AGTC: BUSINESS OVERVIEW
  • 11.23 POSEIDA THERAPEUTICS, INC.
    • TABLE 165 POSEIDA THERAPEUTICS INC: BUSINESS OVERVIEW
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS